Issue 1/2008
Content (20 Articles)
A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer
Se Hoon Park, Eunmi Nam, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
Sequential vinorelbine–capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial
Marwan Ghosn, Joseph Kattan, Fadi Farhat, Fariha Younes, Fadi Nasr, Walid Moukadem, Jamal Gasmi, Georges Chahine
Preclinical studies of treosulfan demonstrate potent activity in Ewing’s sarcoma
Sebastian Werner, Arnulfo Mendoza, Ralf A. Hilger, Miriam Erlacher, Wilfried Reichardt, Andrej Lissat, Claudia Konanz, Marcus Uhl, Charlotte M. Niemeyer, Chand Khanna, Udo Kontny
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis
Richard M. Logan, Rachel J. Gibson, Joanne M. Bowen, Andrea M. Stringer, Stephen T. Sonis, Dorothy M. K. Keefe
Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer
Nanae Tomonaga, Yoichi Nakamura, Hiroshi Soda, Seiji Nagashima, Hirofumi Nakano, Akitoshi Kinoshita, Masaaki Fukuda, Minoru Fukuda, Hiroshi Takatani, Yoshifumi Soejima, Mikio Oka, Shigeru Kohno
In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines
Judith A. Smith, Anjali Gaikwad, Jiang Yu, Judith K. Wolf, Jubilee Brown, Lois M. Ramondetta, Clinton F. Stewart
A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein–Barr virus DNA as a biomarker of efficacy
Brigette Ma, Edwin P. Hui, Ann King, K. F. To, Frankie Mo, Sing F. Leung, Michael Kam, Y. M. Dennis Lo, Benny Zee, Tony Mok, Anil Ahuja, Anthony T. C. Chan
Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia
Peter D. Cole, Richard A. Drachtman, Margaret Masterson, Angela K. Smith, John Glod, John A. Zebala, Stacey Lisi, Drew-Anne Drapala, Barton A. Kamen
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma
Jeeyun Lee, Young-Hyuck Im, Eun Yoon Cho, Yong Sang Hong, Hyo Rak Lee, Hyo Song Kim, Mi-Jin Kim, Kwhanmien Kim, Won Ki Kang, Keunchil Park, Young Mog Shim
Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity
Vincenzo Guarcello, Carmelo Blanquicett, Fardos N. M. Naguib, Mahmoud H. el Kouni
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety
Feng Guo, Stephen P. Letrent, Pamela N. Munster, Carolyn D. Britten, Karen Gelmon, Anthony W. Tolcher, Amarnath Sharma
Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells
Tadahiko Kubo, Shoji Shimose, Toshihiro Matsuo, Akira Sakai, Mitsuo Ochi
Mechanistic study of potentiation of chemotherapy by a haloenol lactone derivative in vitro
Wei Wang, Cindy Q. Xia, Ning Liu, Liang-Shang Gan, Jiang Zheng
Pharmacodynamic model for chemotherapy-induced anemia in rats
Sukyung Woo, Wojciech Krzyzanski, William J. Jusko
Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment
Gerald J. Fetterly, Joel S. Owen, Kim Stuyckens, Julie A. Passarell, Peter Zannikos, Arturo Soto-Matos, Miguel Angel Izquierdo, Juan Jose Perez-Ruixo
Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer
Howard H. Bailey, Steven Attia, Richard R. Love, Terri Fass, Rick Chappell, Kendra Tutsch, Linda Harris, Alcee Jumonville, Richard Hansen, Gary R. Shapiro, James A. Stewart
Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
Tomo Osako, Yoshinori Ito, Shunji Takahashi, Nahomi Tokudome, Takuji Iwase, Kiyohiko Hatake
Bisphosphonates induce apoptosis in CLL cells independently of MDR phenotype
Karina Lani Silva, Deborah Vidal Vasconcellos, Eric Delfraro de Paula Castro, Flavia da Cunha Vasconcelos, Ricardo Bigni, Raquel Ciuvalschi Maia
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer
J. Horti, E. Juhasz, Z. Monostori, K. Maeda, S. Eckhardt, I. Bodrogi